Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis

Annals of Internal Medicine

Volumn 135, Issue 8 II, 2001, Pages 589-593

  Warkentin, T E ^a  

^a HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; HEPARIN; PROTEIN C; THROMBIN ANTITHROMBIN COMPLEX; VITAMIN K GROUP; WARFARIN;

AGED; ARTICLE; CASE REPORT; DEEP VEIN THROMBOSIS; FEMALE; GANGRENE; HUMAN; INTERNATIONAL STANDARD UNIT; LIMB; LUNG CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTOPENIA;

EID: 0035899952     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-135-8_part_1-200110160-00009     Document Type: Article

References (20)

1. Gangrene of lower extremity secondary to extensive venous occlusion
2. Soft tissue necrosis and gangrene complicating treatment with the coumarin derivatives
3. Occult malignancy is associated with venous thrombosis unresponsive to adequate anticoagulation
4. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia
5. Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia
6. Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
7. Laboratory testing for heparin-induced thrombocytopenia
8. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy
9. Trousseau's syndrome. Devastating coagulopathy in the absence of heparin
10. Regulation of blood coagulation
11. Warfarin-induced changes in procoagulant and anticoagulant proteins
12. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy
13. Occult cancer in patients with bilateral deep-vein thrombosis
14. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
15. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor
16. Immune endothelial-cell injury in heparin-associated thrombocytopenia
17. Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines
18. Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: A comparison with standard platelet agonists
19. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa